Tiratricol (Triiodothyroacetic Acid/TRIAC)
Primary Indication and Approval
Tiratricol is specifically approved for treating peripheral thyrotoxicosis in patients with MCT8 deficiency (Allan-Herndon-Dudley Syndrome), not for general hyperthyroidism management. 1 This represents its first and only regulatory approval as of February 2025 in the European Union.
Dosing
For MCT8 Deficiency (Approved Indication)
- Starting dose: 350 μg once daily (available as dispersible tablets)
- Dose escalation: Increase by 350 μg increments progressively
- Target dose: Mean effective dose is 38.3 μg/kg body weight (range 6.4-84.3 μg/kg) 2
- Goal: Achieve serum total T3 concentrations within 1.4-2.5 nmol/L
- Titration frequency: Adjust based on T3 levels until target range achieved
The dose-dependent nature of TRIAC requires individualized titration, as demonstrated in the pivotal trial where patients needed widely varying doses to normalize T3 levels 2.
For Thyroid Hormone Resistance β (Off-Label, Investigational)
- Typical range: 500-3000 μg daily in divided doses
- Pediatric experience: Up to 3.0 mg/day has been used safely in children 3
- Important caveat: TRIAC has a short half-life and rapid clearance, necessitating multiple daily doses for sustained effect 3
Monitoring
Biochemical Parameters
Primary monitoring targets:
- Serum total T3: Target 1.4-2.5 nmol/L for MCT8 deficiency 2
- Free T4 and total T4: Should decrease from baseline
- TSH: Expected to decrease (mean reduction 1.89 mU/L in MCT8 patients) 2
- Reverse T3: Monitor for reduction
Monitoring frequency:
- During dose titration: Every 4-6 weeks (extrapolated from standard hyperthyroidism guidelines 4)
- Once stable: Every 3-6 months
Clinical Parameters
Monitor for:
- Cardiovascular: Heart rate, blood pressure (TRIAC appears to spare cardiac effects compared to T3) 5, 6
- Growth parameters: Weight, height in pediatric patients
- Neurological symptoms: ADHD symptoms may improve in RTHβ patients 3
- Body temperature: Should remain stable (no hyperthermia expected) 5
Contraindications
Absolute Contraindications
Based on FDA labeling for thyroid hormone analogs 7:
- Hypersensitivity to tiratricol or any component
- Pregnancy (thyroid hormone analogs cross placenta)
- Breastfeeding (excreted in breast milk)
Relative Contraindications/Cautions
- Coexisting Graves' disease: One patient in the MCT8 trial developed Graves' disease during treatment, requiring discontinuation 2
- Severe pre-existing cardiac disease: Though TRIAC appears cardioprotective compared to T3, caution is warranted
- Active infections: Serious infections occurred in 39% of MCT8 patients, though unrelated to treatment 2
Adverse Effects
Common (from MCT8 trial) 2
- Treatment-related (13% of patients):
- Transiently increased perspiration
- Irritability
Serious Adverse Events
- 26 serious adverse events in 18/46 patients (39%) - mostly hospital admissions for infections, considered unrelated to TRIAC 2
- One death from pulmonary sepsis/multi-organ failure (unrelated to treatment)
- Cardiovascular effects: Nervousness, cardiac arrhythmia, or tachycardia reported in 4 patients when used off-label at 500 μg daily 8
Alternatives and Context
For MCT8 Deficiency
No effective alternatives exist. Standard thyroid hormone therapy (levothyroxine or T3) cannot enter cells without MCT8 and therefore fails to treat this condition. TRIAC's unique ability to enter cells independent of MCT8 makes it the only viable option 2, 1.
For Thyroid Hormone Resistance β
Standard approach remains observation or symptomatic treatment 4. TRIAC is investigational for this indication:
- Shows promise in reducing hyperthyroid symptoms and normalizing T4/T3 without raising TSH 6
- Reduces resting energy expenditure and symptom scores 6
- Critical limitation: Historical data shows TRIAC has parallel effects on pituitary and peripheral tissues, offering no advantage over supraphysiologic levothyroxine for TSH suppression in most contexts 9
For General Hyperthyroidism
TRIAC is NOT indicated. Standard treatments remain 4:
- Methimazole (first-line antithyroid drug)
- Radioactive iodine (RAI therapy)
- Thyroidectomy
Key Clinical Pitfalls
- Do not use TRIAC for routine hyperthyroidism management - it lacks approval and evidence for this indication
- Recognize the short half-life - requires careful dose titration and potentially multiple daily doses for sustained effect 3
- Monitor for autoimmune thyroid disease development - one case report documents loss of TRIAC efficacy when Graves' disease developed concurrently 10
- Pregnancy testing mandatory - exclude pregnancy within 48 hours before initiating treatment (extrapolated from RAI guidelines 11)
- Infection vigilance - MCT8 patients have high infection rates; maintain high clinical suspicion 2